Johnson & Johnson Press Releases

May 4, 2026

Promising Data from US Pilot Study Shows Planned Impella 5.5 Use is Safe and Feasible in Non-Shock, High-Risk Cardiac Surgery Patients

May 4, 2026

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus antidepressant therapy Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials

May 4, 2026

Johnson & Johnson to Present New Data Spanning Vision Portfolio at ARVO 2026

• Seventeen company presentations highlight breadth of vision portfolio spanning myopia control, ACUVUE contact lenses and TECNIS IOLs • Johnson & Johnson to debut new insights linking peripheral optics to functional vision

Innovative Medicine

May 1, 2026

Johnson & Johnson Announces FDA Approval of STELARA® for Pediatric Crohn’s Disease

April 30, 2026

Johnson & Johnson statement on investigational programs in large B-cell lymphoma

April 30, 2026

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Innovative Medicine

April 29, 2026

Johnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026

· Late-breaking Phase 3 PROTEUS data for ERLEADA® (apalutamide) selected to open the ASCO plenary, signaling a potential paradigm shift for high-risk prostate cancer in patients receiving curative-intent surgical treatment · Results from MajesTEC-9, the second positive Phase 3 study of TECVAYLI® (teclistamab-cqyv), reinforce TECVAYLI® regimens as potential new standard of care in multiple myeloma as early as second line · Pivotal OrigAMI-4 results evaluating RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) reinforce its potential to redefine treatment in advanced head and neck cancer

April 27, 2026

Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference

Innovative Medicine

April 27, 2026

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemia IMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemia

Innovative Medicine

April 27, 2026

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA® studies

Search Results

No Results

Press releases

Press Releases